Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Sehgal, Kartik, Anushi Bulumulle, Heather Brody, Ritu R Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C McDonald, et al. 2021. “Association of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non-Small-Cell Lung Cancer.”. Clinical Lung Cancer 22 (3): e379-e389.